摘要目的 比较人真核细胞翻译起始因子4E(eIF4E)在急性髓系白血病(AML)与非肿瘤对照组之间、不同AML亚型之间和诱导治疗前后的表达差异,以及eIF4E表达与AML其他分子生物学异常的相互关系.方法 采集155例初诊AML患者及20例非肿瘤对照者骨髓标本,应用反转录聚合酶链反应(PCR)法检测eIF4E的表达.所有AML患者均进行基因突变检测.结果 155例初诊AML患者中,101例(65.2％)eIF4E阳性表达.进入诱导治疗的132例中,95例(72.0％)经诱导治疗达完全缓解,其中12例(17.6％)eIF4E由阳性转为阴性.非肿瘤对照者eIF4E均阴性.亚型分析中,M4、M5型AMLeIF4E阳性率分别为75.0％(15/20)和80.8％(21/26),高于其他亚型AML(59.6％,65/109),但差异无统计学意义(P＞0.05).初诊AML患者中,26例FLT3-ITD基因突变阳性,eIF4E表达与FLT3-ITD基因突变无相关性(P＞0.05).结论 多数初诊AML患者eIF4E阳性,诱导治疗达完全缓解后部分AML患者eIF4E转阴.各亚型间eIF4E表达无差异.eIF4E与FLT3-ITD分子指标无相关性.

abstractsObjectives To analysis the expression difference of eIF4E in bone marrow between the acute myeloid leukemia (AML) and the non-tumor patient,before and after induction therapy,and the different subtypes of AML,and to explore the relation between eIF4E and other molecular biology abnormalities in AML.Methods The bone marrow specimens of newly diagnosed AML and non-tumor control patients were collected.The expression level of eIF4E was detected by RT-PCR.Results The positive rate of eIF4E was 65.2 ％ (101/155) in AML.eIF4E turned to negative in 12 patients (17.6 ％) who got complete remission after induction therapy.eIF4E was negatively expressed in bone marrow of the nontumor control patients.The positive rates of eIF4E were 75.0 ％ (15/20) and 80.8 ％ (21/26) in M4 and M5 type AML,respectively,and was 59.6 ％ (65/109) in other subtype AML (P ＞ 0.05).FLT3/ITD gene mutation was found in 26 cases of newly diagnosed AML.The eIF4E expression and FLT3-ITD gene mutation were independent each other (P ＞ 0.05).Conclusions eIF4E is positive in most of the newly diagnosed AML and turns to negative in part of AML achieving complete remission.The expression of eIF4E is no difference among different subtype of AMLs.eIF4E and FLT3-ITD gene mutation are independent each other.